Plasma proteomics improves AMI risk stratification in T2D, and FGF5 may play a role in cardiovascular risk in Asian populations.
Abstract
Background
Individuals with type 2 diabetes (T2D) have increased risk of acute myocardial infarction (AMI). Cardiovascular risk within T2D is heterogeneous and not fully explained by conventional risk factors, highlighting the need for improved biological risk stratification.
Objectives
The authors aimed to identify circulating proteins associated with incident AMI in T2D, evaluate their incremental predictive value, and explore potential causal relationships.
Methods
In 1,830 adults with T2D from the prospective SMART2D cohort, 1,457 plasma proteins were quantified at baseline using Olink proximity extension assays. Participants were followed for incident AMI through linkage with the Singapore Myocardial Infarction Registry over a median of 10.2 years (IQR: 9.1-10.7). Multivariable Cox regression assessed protein-AMI association. Incremental predictive performance was evaluated using Harrell's C-statistic, likelihood ratio tests (LRTs), net reclassification index (NRI), and integrated discrimination index (IDI). Two-sample Mendelian randomization, using cis-protein qualitative-trait loci from SMART2D and outcome data from Biobank Japan (14,992 cases; 146,214 controls), examined causal associations.
Results
During follow-up, 223 participants (12.2%) developed AMI. Seventeen proteins were independently associated with AMI after Bonferroni correction (P < 3.43 × 10-5), with the strongest associations observed for NEFL (HR: 1.70, 95% CI: 1.43-2.01), EDA2R (HR: 2.25, 95% CI: 1.69-2.97), and CHRDL1 (HR: 2.69, 95% CI: 1.83-3.94). An 8-protein panel improved risk classification beyond clinical variables (LRT P = 0.002; IDI: 0.049, 95% CI: 0.022-0.128, P = 0.002; and NRI: 0.318, 95% CI: 0.112-0.411, P = 0.008). Genetically predicted plasma FGF5 levels were associated with myocardial infarction risk.
Conclusions
Plasma proteomics improves AMI risk stratification in T2D, and FGF5 may play a role in cardiovascular risk in Asian populations.
A hypothesis-generating analysis establishes an interpretable biochemical profile of RBT components independently associated with near-term AMI in DM patients, and Prospective external validation is required before these findings can inform clinical practice.
Peter Y. M. Woo, Chak-Ho Lo, Adrian J. Y. Ng et al.· npj Cardiovascular Health· 0 citations
In older adults, circulating biomarkers and PGSs provide cumulative information for CVD risk prediction, contributing differently to discrimination and risk reclassification.
Cheng-Long Yu, C. Tran, J. Neumann et al.· Atherosclerosis· 0 citations
Distinct metabolomic profiles were associated with incident PAD and CLI years before clinical onset, highlighting dysregulated glycemic control, impaired redox balance, and altered lipid remodeling as key underlying pathways and suggest that circulating metabolites may serve as early indicators of metabolic health rele...
E. Bansah, Xiao Hu, S. Ballew et al.· Arteriosclerosis, Thrombosis...· 0 citations
In participants with T2D and LFI, adding a metabolomic signature to SCORE2-Diabetes produced a statistically significant but moderate improvement in risk discrimination, which supports further evaluation in independent cohorts and prospective impact studies.
Mei-Li Li, Yan-Yan Shen, You-Wei Huang et al.· Frontiers in Endocrinology· 0 citations
Background
The C-reactive protein-triglyceride glucose index (CTI) has recently been introduced as a novel composite biomarker that integrates inflammation and insulin resistance. However, the association between CTI and incident cardiovascular disease (CVD) in individuals with hypertension remains unclear.
Methods
W...
Yin Wang, Jie Luo, Zhao-Fu Tan et al.· Endocrinology and Metabolism· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.